This Funding Opportunity Announcement (FOA) solicits applications that support testing new therapeutic uses for experimental drugs or biologics (Assets) across a broad range of human diseases unique to pediatric populations.
This innovative program allows investigators to propose new therapeutic
uses for Assets from pharmaceutical company partners.
Strong applications will include scientific evidence that modulation of an Assets target will have a positive impact on the disease/condition.
An X02 pre-application is the first step in the application process for RFA-TR-17-002 and RFA-TR-17-00 3. X02 pre-applications will be evaluated by outside experts.
Investigators whose X02 pre-applications are judged to be the most meritorious and relevant to NIH program priorities will be notified of the opportunity to submit a UG3/UH3 application under this FOA.
The initial UG3 award will support the development of rigorous, pre-clinical efficacy studies and clinical trial planning activities.
If UG3 pre-clinical milestones are met, the UH3 award may be made to support clinical trials.